12May 2020

QUOI DE NEUF A PROPOS DE LHEPATITE VIRAL D:MISE AU POINT

  • Faculte de Medecine et de Pharmacie, Universite Sidi Mohamed Ben Abdallah de Fes.
Crossref Cited-by Linking logo

  • References
  • Cite This Article as
  • Corresponding Author
  1. Brahmania M, Feld J, Arif A, et al. New therapeutic agents for chronic hepatitis?,B. Lancet Infect Dis 2016;16:e10‑
  2. Romeo R, Del Ninno E, Rumi M, et al. A 28-Year study of the course of hepatitis B infection : A risk factor for cirrhosis and hepatocellularcarcinoma. Gastroenterology 2009;136:1629‑
  3. Pir Ahmad Shah, Saad Choudhryet al , An update on the management of chronic hepatitis D, Gastroenterology Report, 7(6), 2019, 396?402?.
  4. Rizzetto M, Ciancio A. Epidemiologyof hepatitis D. Semin Liver Dis 2012;32: 211‑
  5. RizzettoM,CaneseMG,Aric?S,CrivelliO,TrepoC,BoninoF,etal.Immunofluorescencedetectionofnewantigen?antibody system (delta/anti-delta)associatedtohepatitisB virus inliverandinserumofHBsAgcarriers. Gut 1977;18(12):997?1003.
  6. RizzettoM,ShihJW,GockeDJ,PurcellRH,VermeG,GerinJL.Incidenceandsignificance of antibodiestodeltaantigeninhepatitisB virus infection. Lancet1979 ;2(8150):986?90.
  7. RizzettoM,PurcellRH,GerinJL.Epidemiol- ogyofHBVassociateddeltaagent: geogra- phicaldistributionofanti-deltaandprevalenceinpolytransfusedHBsAgcarriers. Lancet 1980;1(8180):1215?8.
  8. RizzettoM,HoyerB,CaneseMG,ShihJW, PurcellRH ,GerinJL. Deltaagent: association of deltaantigenwithhepatitisBsurfaceanti- gen and RNAinserumofdelta-infectedchim- panzees.ProcNatlAcadSciUSA1980;77 (10):6124?8.
  9. Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus : A review. World J Hepatol 2013;5:666‑
  10. Pascarella S, Negro F. Hepatitis D virus : An update. Liver Int 2011;31:721.
  11. Fattovich G, Gut 2000?,journees fran?aises de luttes contre les hepatites virales .
  12. EuropeanAssociationForTheStudyOfThe Liver .EASL clinical practice guidelines: Man- agementofchronichepatitisBvirusinfection. J Hepatol2012;57(1):167?85.
  13. Hughes SA,WedemeyerH,HarrisonPM. Hepatitisdeltavirus .Lancet 2011;378 (9785):73?85
  14. OliveroA,SmedileA.Hepatitisdeltavirusdiagnosis. Semin Liver Dis 2012;32(3):220?7.
  15. Moradpour D, Negro F. Hepatite D : oubliee mais pas disparue. Rev Med Suisse 2010;6:1656‑
  16. Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, et al. Anti-HDV IgM as a marker of diseaseactivity in hepatitis delta. PloS One 2014;9(7):e101002.
  17. SorianoV,VispoE,Sierra-EnguitaR,Mendoza de C,Fern?ndez-MonteroJV,etal.Efficacyofprolongedtenofovirtherapyonhepatitis delta inHIV-infectedpatients.AIDSLondEngl 2014;28(16):2389?94.
  18. Calle SerranoB,Gro?hennigA,HomsM, Heidrich B,ErhardtA,DeterdingK,etal. Developmentandevaluationofabaseline- event-anticipationscoreforhepatitisdelta.J Viral Hepat2014;21(11):e154?63.
  19. Abbas Z, Abbas M. Management of hepatitis delta: Need for noveltherapeutic options. World J Gastroenterol 2015; 21:9461‑
  20. European Association for Study of LiverAsociacionLatinoamericana para el EASL-ALEH Clinical Practice Guidelines: Non-invasivetests for evaluation of liver diseaseseverity and prognosis.Journal of Hepatology????????? 2017 vol. 67 j 370?398
  21. STEFANO et al ,GUGLIELMI al,? Jean-Louis FROSSARD et al? et FRANCESCO? NEGRO et al?? ,Rev Med Suisse 2016 ; 12 : 1415-8
  22. Bogomolov P, Alexandrov A, Voronkova?,N, et al. Treatment of chronic hepatitis D withthe entry inhibitormyrcludexB ,firstresults of a Phase Ib / IIastudy. J HepatolPublished Online First : 27 April 2016.
  23. Bazinet M, Pantea V, Cebotarescu V, et al. Significantreduction of HBsAg and HDV RNA by the nucleicacidpolymer REP 2139 in caucasian patients with chronic HBV / HDV co-infection. J Hepatol 2015; 62:S257‑8.
  24. https://www.uptodate.com/contents/treatment-and-prevention-of-hepatitis-d-virus-infection/print,Treatment and prevention of hepatitis D virus infection.2020.

[Maryame Elkhayari, Nada. Lahmidani, Hakima Abid, Mariya Lahlali, Asmae Lamine, Mounia Elyousfi, Dafr-Allah Benajah, Mohammed El Abkari and Adil Ibrahimi (2020); QUOI DE NEUF A PROPOS DE LHEPATITE VIRAL D:MISE AU POINT Int. J. of Adv. Res. 8 (May). 505-511] (ISSN 2320-5407). www.journalijar.com

EL KHAYARI MARYAME
Service d’hépato-gastro-entérologie, CHU Hassan II de Fès. Faculté de médecine et de pharmacie, Université sidi Mohamed ben Abdallah de Fès.

DOI:

Article DOI: 10.21474/IJAR01/10955      
DOI URL: https://dx.doi.org/10.21474/IJAR01/10955

Download Full Paper

Download PDF No. of Downloads: 15 | No. of Views: 41